Obesity最新文献

{"title":"Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps","authors":"Robert L. Dubin,&nbsp;Tierra N. Sanders,&nbsp;Hunter M. Schwab,&nbsp;Steven B. Heymsfield,&nbsp;Frank L. Greenway","doi":"10.1002/oby.70212","DOIUrl":"10.1002/oby.70212","url":null,"abstract":"<p>The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight-based outcomes but by changes in body composition. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can be quantified by changes in percent fat/fat-free mass as a total of body weight. The amount of weight that is lost as % fat-free mass (% FFML) with diet-induced weight loss is ~25% but is extremely variable. Our aim was to provide an update to our previous report assessing changes in body composition using GLP-1 RA-based agents. In our updated review of 40 DXA-based reports, we found the mean (SD) % FFML was 29.1% (19.0%). Similar to our previous report, we found that the changes in body composition using these agents remain in the upper range of expected % FFML using other nonsurgical interventions for obesity. Functional measures of strength and performance and assessing body composition effects of future GLP-1-based agents are needed to understand the continued gaps that exist in determining the impact these treatments have, particularly in high-risk populations.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"51-63"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective","authors":"Fernanda Baeza Scagliusi,&nbsp;Bruno Gualano,&nbsp;Pernille Andreassen,&nbsp;Cindi SturtzSreetharan,&nbsp;Sissel Due Jensen,&nbsp;Alexandra Brewis","doi":"10.1002/oby.70069","DOIUrl":"10.1002/oby.70069","url":null,"abstract":"<p>The off-label use of glucagon-like peptide-1 receptor agonists (GLP-1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses around the off-label use of GLP-1ra to an individual goal of slimness rather than health. We propose that off-label GLP-1ra use by people with normative or mildly elevated weight reveals deeper tensions between scientific progress, stigma, and cultural ideals of the body. Understanding this phenomenon requires moving beyond biomedical efficacy to interrogate the psychological, behavioral, and sociopolitical implications of pharmacological thinness. Cross-cultural and intersectional approaches from the social sciences are key to understanding this emergent phenomenon.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"9-12"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes","authors":"Ying Lu,&nbsp;Hao Dai,&nbsp;Huilin Tang,&nbsp;William T. Donahoo,&nbsp;Thomas J. George,&nbsp;Ramon C. Sun,&nbsp;Sizun Jiang,&nbsp;Aik Choon Tan,&nbsp;Yi Guo,&nbsp;Jonathan D. Licht,&nbsp;John M. Allen,&nbsp;Kelvin P. Lee,&nbsp;Jingchuan Guo,&nbsp;Jiang Bian","doi":"10.1002/oby.24366","DOIUrl":"10.1002/oby.24366","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The real-world evidence on the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cancer risk remains limited and mixed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 2013–2020 national Medicare claims data, we included cancer-naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP-1 RA, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase 4 inhibitor (DPP4i) and conducted 1:1 propensity score matching for confounding adjustment. Cox proportional hazards models were used to estimate hazard ratios (HR) of nine obesity-associated cancers (thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, and prostate cancer).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the matched GLP-1RA versus SGLT2i cohort (<i>n</i> = 21,362 pairs), GLP-1RA users had similar overall cancer risk with SGLT2i users (HR, 1.03 [95% CI, 0.95–1.12]), but GLP-1RAs were associated with an increased kidney cancer risk (HR, 1.43 [1.06–1.92]). In the matched GLP-1RA versus DPP4i cohort (<i>n</i> = 20,962 pairs), the GLP-1RA versus DPP4i comparison showed no significant difference in overall cancer risk (HR, 0.96 [0.89–1.04]) but revealed a significantly elevated endometrial cancer risk (HR, 1.55 [1.01–2.37]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GLP-1RAs might be associated with an increased risk of certain cancer types. Future studies are needed to validate the potential tumorigenic risk associated with GLP1-RAs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"75-87"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials","authors":"Chengwen Li,&nbsp;Chu Lin,&nbsp;Xiaoling Cai,&nbsp;Fang Lv,&nbsp;Wenjia Yang,&nbsp;Linong Ji","doi":"10.1002/oby.70054","DOIUrl":"10.1002/oby.70054","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity-associated cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024. Relative risks were calculated using a random-effects model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis included 25 randomized controlled trials with 40,731 participants. Compared with placebo, AOMs showed no association with the risk of overall obesity-related cancer (RR = 1.03, 95% CI: 0.78 to 1.37) or site-specific cancer. Consistently, every 5 kg weight reduction mediated by AOMs was not associated with the risk of overall obesity-related cancer (RR = 0.97, 95% CI: 0.84 to 1.12) or site-specific cancer. However, subgroup analysis revealed that coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity-associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97), and every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity-associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Weight reduction mediated by current AOMs was not associated with a reduced risk of overall or site-specific obesity-associated cancer in patients with overweight or obesity, while a decreased risk of overall obesity-associated cancer was observed in coagonist users.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"16-24"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence","authors":"Janice Bidesie,&nbsp;Erik Oudman","doi":"10.1002/oby.70256","DOIUrl":"10.1002/oby.70256","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies. Wernicke's encephalopathy (WE), caused by thiamine deficiency, is a rare but potentially fatal neurological disorder that may result in irreversible cognitive impairment if not promptly recognized and treated. Recently, cases of WE associated with semaglutide use have been reported. This study aimed to systematically review published case reports of WE occurring after semaglutide treatment for obesity from an endocrinological drug safety perspective.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature search was conducted in PubMed, Embase, CINAHL, and Scopus according to PRISMA guidelines. Case reports were included when semaglutide was prescribed for obesity and the presentation was consistent with WE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Six cases were identified. All patients experienced prolonged gastrointestinal symptoms and substantial weight loss before neurological deterioration. Common manifestations included altered mental status and oculomotor abnormalities. Outcomes were poor in several cases, including progression to Korsakoff syndrome or death.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Clinicians should remain vigilant for thiamine deficiency in patients with persistent gastrointestinal intolerance or rapid weight loss during GLP-1 treatment, as early parenteral thiamine administration is essential to prevent irreversible neurological sequelae.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"64-69"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Competence and GLP-1RA Weight Management Engagement: Mixed-Methods Insights From Six Patient Groups","authors":"Jane A. McElroy,&nbsp;Isabella Bertarelli,&nbsp;Chloe Maltagliati,&nbsp;Jamie Smith,&nbsp;Regina DePietro","doi":"10.1002/oby.70275","DOIUrl":"10.1002/oby.70275","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore patients' perspectives on GLP-1 receptor agonists (GLP-1RAs) for weight loss across the continuum of contemplating use to discontinuation, with and without achieving weight loss goals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From June to October 2025, participants completed a 30-item survey and ~30-question semi-structured interview regarding their perceptions of GLP-1RAs for weight loss. Interviews were tailored to six GLP-1RA groups: (1) considering use; (2) &lt; 3 months on therapy; (3) ≥ 3 months on therapy without achieving weight loss goal; (4) ≥ 3 months on therapy with achieving weight loss goal; (5) discontinued without achieving goal; and (6) discontinued after achieving goal. Qualitative coding and thematic analysis were conducted in Dedoose (9.0.107); quantitative analyses used SAS 9.4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 185 participants consented, and 141 completed data collection (76%). Descriptive profiles suggested heterogeneity across psychosocial and behavioral domains. Groups 3 and 4 showed stronger profiles (higher perceived competence, intrinsic motivation, and self-monitoring). After false discovery rate adjustment across 78 comparisons, perceived competence was the only statistically significant differentiator: Group 1 was lower (<i>z</i> = −3.15; <i>q</i> = 0.0347) and Group 4 higher (<i>z</i> = 4.44; <i>q</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Findings underscore the importance of tailoring behavioral support to individuals' stage of engagement in GLP-1RA-supported weight loss journeys.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 9","pages":"1759-1771"},"PeriodicalIF":4.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens","authors":"Abigail B. Lodrigues,&nbsp;Alissa V. Russell,&nbsp;Shelby Tungate Lopez,&nbsp;Anne M. Komé","doi":"10.1002/oby.70253","DOIUrl":"10.1002/oby.70253","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 9","pages":"1684-1686"},"PeriodicalIF":4.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Weight-Loss Targets for Metabolic Syndrome Reversal: A BMI-Normalization Achievement Rate-Based Cohort Study","authors":"Junfeng Qi,&nbsp;Longzhu Xiong,&nbsp;Chuansha Wu,&nbsp;Xiaojie Sun,&nbsp;Junlin Li,&nbsp;Likun Ren,&nbsp;Chaoliang Yi,&nbsp;Yuqin Shi,&nbsp;Ling Zhang,&nbsp;Xiongfei Pan,&nbsp;Ting Zhou,&nbsp;Shuzhen Zhu","doi":"10.1002/oby.70269","DOIUrl":"10.1002/oby.70269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore personalized weight-loss targets for metabolic syndrome (MetS) reversal by introducing the BMI-normalization achievement rate (BMI-NAR), a novel baseline-BMI-scaled metric.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a longitudinal cohort of 7340 adults with overweight/obesity and MetS from the ChinaHEART project, BMI-NAR was defined as the percentage of progress toward a normal BMI (&lt; 24 kg/m²). Logistic regression and restricted cubic splines assessed the dose–response relationship between BMI-NAR and MetS reversal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Each 50% increase in BMI-NAR was significantly associated with MetS reversal (overall: OR = 1.10, 95% CI: 1.07–1.12; overweight: OR = 1.08, 95% CI: 1.06–1.11; obesity: OR = 2.36, 95% CI: 2.00–2.80). The probability of reversal increased steeply beyond exploratory minimum effective thresholds (37% BMI-NAR for overall; 53% for overweight; 22% for obesity), with benefits observed up to ~165% in the total population, beyond which data were sparse. No clear upper plateau was identified in populations with overweight and obesity. These exploratory thresholds translate into personalized weight-loss targets: a minimum reduction of 2%–8% for typical overweight (baseline BMI 25–27.99 kg/m²) and 3%–9% for obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MetS reversal does not require full BMI normalization. BMI-NAR provides a hypothesis-generating, quantifiable framework for exploring personalized minimum effective weight-loss goals in this high-risk population. However, external validation is required before clinical application.</p>\u0000 \u0000 <div>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 9","pages":"1718-1731"},"PeriodicalIF":4.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Characteristics and Engagement in CGM-Supported Virtual Weight Management","authors":"Chen Zheng,&nbsp;Jiage Niu,&nbsp;Yingying Xu","doi":"10.1002/oby.70258","DOIUrl":"10.1002/oby.70258","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 9","pages":"1682-1683"},"PeriodicalIF":4.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity","authors":"Hong Chen,&nbsp;Ling Li,&nbsp;Junqing Zhang,&nbsp;Shaihong Zhu,&nbsp;Marc-André Cornier,&nbsp;Jonathan Q Purnell","doi":"10.1002/oby.70263","DOIUrl":"https://doi.org/10.1002/oby.70263","url":null,"abstract":"<p>An international panel of experts from the U.S. and China convened to discuss the <i>2026</i> <i>TOS–OMA–OAC Expert Guidance Statement on the Pharmacological Management of Obesity,</i> focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long-term care. Panelists reached a consensus that obesity should be recognized as a chronic and progressive disease, for which pharmacotherapy is lifelong once initiated, as discontinuation consistently leads to weight regain and loss of metabolic benefit. The discussion highlighted a shift toward treating obesity itself as an upstream intervention capable of modifying multiple obesity-related complications, with greater weight loss generally conferring greater clinical benefit. Visceral adipose tissue emerged as a particularly relevant therapeutic target, especially in Asian populations, where substantial metabolic risk may be present at lower BMI levels. Panelists noted heterogeneity in treatment response and that eventual weight-loss plateaus should be anticipated as evidence of maximal effectiveness rather than medication failure. The panel endorsed an individualized, stepwise approach integrating pharmacotherapy and metabolic surgery as complementary strategies. Finally, the panel emphasized that translating therapeutic advances into real-world benefit will require addressing practical barriers related to policy, access, affordability, and stigma to ensure effective care reaches those who need it most.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 9","pages":"1708-1717"},"PeriodicalIF":4.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}